Tailored Drug Titration through Artificial Intelligence
Tailored Drug Titration through Artificial Intelligence
批准号:
9341533
负责人:
Gabriela Voskerician
金额:
$84.9万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-01 至 2019-03-31
关键词:
Admission activityAdoptionAdverse effectsAffectAgeAmericanArtificial IntelligenceBlood PressureBusinessesCaringClinicalClinical TrialsComorbidityComputerized Medical RecordCustomDataDiseaseEffectivenessEmergency SituationEmergency department visitEnsureEthnic OriginEventFrequenciesGenderGenerationsGoalsHealthHealth Insurance Portability and Accountability ActHealthcareHealthcare SystemsHeart failureHospital CostsHospitalizationHypersensitivityHypertensionIncidenceIntelligenceIntervention StudiesLaboratoriesLife StyleLogicMeasuresMedicalMedical centerModelingMyocardial InfarctionOffice VisitsPatient CarePatientsPharmaceutical PreparationsPhysiciansPositioning AttributePreventive careProtocols documentationQuality of CareQuality of lifeRandomizedRandomized Clinical TrialsRiskRisk stratificationSan FranciscoScheduleSecureSiteStrokeSurveysSymptomsSystemTechnologyTimeTitrationsUpdateVisitarmbaseblood pressure reductionblood pressure regulationclinical efficacycloud basedcommercial applicationcomputerized data processingcostdesignhealth care deliveryhealth care servicehealth datahypertension treatmentimprovedinnovative technologiesmedication compliancenovelpatient stratificationprimary outcomeresponsescale upsecondary outcomesuccesstoolweb services
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Optima Integrated Health Inc. (Optima) proposes to demonstrate the clinical efficacy of the decision support
technology for medication treatment optimization it validated in a pilot clinical trial, optima4BP. optima4BP is
designed as a physician decision/action support aid in timely and safely optimizing medication treatment
independent of in-office visits, for patients with uncontrolled hypertension (HTN). optima4BP is designed to
reduce preventable hospitalizations and the associated incidence of stroke, heart failure (HF) or myocardial
infarction (MI) events resulting from high blood pressure (BP) above goal. Uncontrolled HTN affects 34 million
Americans. The cost of HTN-associated hospitalizations is $113 billion, or 15% of all hospital costs, with >135
million Emergency Dptm. (ED) visits. optima4BP will improve the quality of life for uncontrolled HTN patients,
and reduce this massive burden on the US healthcare system. Our long term objective is to help drive the
transformation from the reactive pay-for-service healthcare paradigm to one that emphasizes preventative care
through personalized health surveillance, assessment, and action via timely and safely optimized medication
treatment. Our specific aims include: Aim (1) demonstrating the efficacy of optima4BP in a randomized clinical
trial (n=300 patients) deployed at UC San Francisco Medical Center. Patients will be randomized to an
enhanced care (EC) arm or an optima4BP arm (O4BP). All patients will use Omron10 BP arm cuff to remotely
measure their BP. For the patients in the EC arm, physicians will be provided with a monthly summary of the
Omron10 data. For patients in the O4BP arm, aside from the BP monthly summary, physicians will receive (a)
a risk stratified patient roster, (b) next step actions in medication optimization for each patient, and (c) access
to optima4BP's secure web-service medication treatment modeling to investigate how changing current patient
data could affect medication choice (e.g., change in medication choice if BP goal is lowered). We will then
examine the BP value reduction between arms (success:>7 mmHg decreased systolic; >4 mmHg decreased
diastolic of O4BP vs. EC), along with secondary outcomes between O4BP and EC: medication treatment
action frequency; ED admissions due to HTN-related symptoms and associated hospitalizations for stroke, HF
or MI; and overall cost of HTN management. Aim (2) optima4BP data processing steps will be optimized to
scale-up its capability to >1000/day patient cases processing power. 3 specific optimization processing tools
will be developed: Optima Extract, Transform, and Load (OETL); Optima Survey Generator (OSG), and Optima
Message Builder (OMB). OETL will provide streamlined scheduling logic to extracting data from Epic® EMR
(electronic medical record), optimize data mapping scripts within optima4BP, and optimize data uploading
protocols. OSG will optimize the current generation protocol for patient surveys, patient response, and
assignment of patient responses to specific processing modules. OMB will ensure streamlined scheduling of
risk stratification updates and scheduled delivery to physician In-Basket messaging system within Epic® EHR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
-
批准号:10641684
-
项目类别:
-
资助金额:$124.64万
-
财政年份:2022
-
负责人:Gabriela Voskerician
-
依托单位:
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
-
批准号:10381898
-
项目类别:
-
资助金额:$103.49万
-
财政年份:2022
-
负责人:Gabriela Voskerician
-
依托单位:
ARTERY Outcomes: tAilored dRug Titration through artificial intElligence: an inteRventional studY
-
批准号:10001603
-
项目类别:
-
资助金额:$65.48万
-
财政年份:2019
-
负责人:Gabriela Voskerician
-
依托单位:
optima4heart: pharmacological intervention and transition of care in cardiovascular disease management
-
批准号:9770702
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2019
-
负责人:Gabriela Voskerician
-
依托单位:
PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target
-
批准号:10159301
-
项目类别:
-
资助金额:$71.6万
-
财政年份:2018
-
负责人:Gabriela Voskerician
-
依托单位:
PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target
-
批准号:9901106
-
项目类别:
-
资助金额:$75.02万
-
财政年份:2018
-
负责人:Gabriela Voskerician
-
依托单位:
Personal Mobile Diabetes Management System(PMDMS): IN-TRACK
-
批准号:8311248
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2012
-
负责人:Gabriela Voskerician
-
依托单位:
海外基金